Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Claridgeon Dec 04, 2019 10:08pm
97 Views
Post# 30423406

RE:RE:Similar much.... time to tweet @ Bio Optics World

RE:RE:Similar much.... time to tweet @ Bio Optics World Eoganacht ... Nice observation about Dr.Gasser in that study.  There was also Prof. Sadler from UK (univ. of Warwick).  His 2019 article:

Simply shining light on 'dinosaur metal' compound kills cancer ...



was a repeat of what I had seen in 2015, via this article then:

Cancer drug 49 times more potent than Cisplatin -- ScienceDaily



Dr. McFarland knows him, just like she knows Dr. Gasser.

Not much f a threat, as far asI'm concerned.  And we're listed on an exchange in what is an amazing entry point that you wouldn't have the possibility to obtain if one private biotech would IPO on an exchange.


______________________

Eoganacht - (12/4/2019 5:29:54 PM)
RE:Similar much.... time to tweet @ Bio Optics World
I notice that Gilles Gasser was also involved in this study. He was a coauthor with Dr. McFarland, Dr. Mandel and Roger Dumoulin-White in the recent ScienceDirect article.

It looks like they are still in the petri dish stage.

Targeted photoredox catalysis in cancer cells


LaserStock29 wrote: Photodynamic therapy Iridium Oct 17/2019


A team of researchers at the University of Warwick (Coventry, England), in collaboration with colleagues at Sun Yat-Sen University (Guangdong, China), Shenzhen University (Shenzhen, China), PSL Research University (Paris, France), the University of Zurich (Zurich Switzerland), and Heriot-Watt University (Edinburgh, Scotland), has developed a phototherapy technique to activate a cancer-killing compound of iridium that attacks a vital energy source in cancer cells even under hypoxia, significantly opening up the range of cancers that can be treated using the technique.

 

The technique could lead to another tool for clinicians to use in the fight against cancer, and potentially even vaccinate patients against future cancers.

 

Phototherapy, also known as photodynamic therapy (PDT), uses light to kill cancer tumors in the body by activating a chemical compound called a photosensitizer, which creates species that can attack cancer cells in the presence of light. Using this method, clinicians can direct the light to specific regions of the cancer tumor and spare normal tissue from damage.

 

Current methods mainly rely on the presence of oxygen and many tumors are hypoxic, which means that they are deficient in normal oxygen often due to poor blood supplies. Recognizing this, the international research team developed a compound of the metal iridium that will kill cancer cells in culture, even when oxygen concentration is low.

 

The technique can treat any tumors where light can be administered, and would be particularly suited to treat bladder, lung, esophageal, brain, and skin cancers.

BEEN THERE............ DONE THAT!!!!!!!!!!!!!!!!!!!!!!

"There is an increasing interest in reducing the side effects of cancer treatment as much as possible and anything that can be selective in what it targets will help with that," says Professor Peter Sadler from the University of Warwick's Department of Chemistry. "The compound that we have developed would not be very toxic at allwe would give it to the cancer cells, allow a little time for it to be taken up, then we would irradiate it with light and activate it in those cells. We would expect killing of those cancer cells to occur very quickly compared with current methods." 

 

Once light-activated, the iridium compound attacks the energy-producing machinery in the cancer cellsa vital co-enzyme called nicotinamide adenine dinucleotide (NADH)—and catalytically destroys that co-enzyme or changes it into its oxidized form. This upsets the energy-producing machinery in a cancer cell and effectively cuts off the tumor's power source. 

 

Our bodies need NADH to generate energycancer cells have a very high requirement for NADH, as they need a lot of energy to divide and multiple rapidly. 

 

The researchers even found that the compound still works in the presence of oxygen, by converting it into a 'toxic' type of oxygen that will kill the cancer cells.

 

The team of scientists also noted that as the cancer cells die, they change their chemistry in such a way that they will generate an immune reaction in the body, what is known as an immunotherapeutic response. This suggests that those treated by this technique might be immunized against attack by that cancer, and will be investigated further in future research.

 

"The ability of metal compounds to induce an immunogenic response in the body that may effectively vaccinate a person against future attack by cancer is an exciting development. It is very speculative, but we are looking further into the hallmarks of that," Sadler adds.

IT AINT SPECULATIVE OVER HERE!!!!!!!!

Full details of the work appear in the journal Nature Chemistry.

full article



---------------
 Medtronic and their Supernavigate device and a Global partnership to tackle the Lung indication utilizing their innovation centre in 2020... :-)

my no.1 pick 

#TeamGetRich2020



Theres an old saying.. when a breakthrough occurs.. many people from different spots on earth are doing the same thing

Convergent Evolution

I already mentioned this before... its here, its now.. it's our time.. $$$








  


Bullboard Posts